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Inhibition of Lysophosphatidic Acid Receptor-2 Expression by RNA 
Interference Decreases Lysophosphatidic Acid-induced Urokinase 
Plasminogen Activator Activation, Cell Invasion, and Migration in Ovarian 
Cancer SKOV-3 Cells
Aim To explore the role of lysophosphatidic acid receptor-2 
(LPA2) in regulating lysophosphatidic acid (LPA)-induced uro-
kinase plasminogen activator (uPA) activation, cell invasion, and 
migration in human ovarian cancer cell line SKOV-3.
Methods SKOV-3 cells were stimulated with LPA. Cell superna-
tant uPA level and activity were measured using enzyme-linked 
immunosorbent assay. LPA2 mRNA expression was inhibited 
with LPA2-specific small interfering RNA (siRNA) and examined 
using semiquantitative reverse transcriptase-polymerase chain re-
action. LPA-induced cell invasion and migration in transfected 
cells were evaluated by a Matrigel invasion chamber and a Tran-
swell chemotaxis chamber, respectively.
Results LPA stimulation significantly enhanced in vitro uPA ac-
tivity in time- and dose-dependent manner. The levels of LPA-in-
duced uPA protein decreased by 55% in LPA2 siRNA-transfected 
cells compared with negatively transfected cells at 24 hours after 
being treated with 80 μmol/L LPA (0.75 ± 0.03 vs 0.34 ± 0.04, 
P = 0.004). In the LPA2 specific siRNA-transfected SKOV-3 cells, 
LPA treatment at 80 μmol/L induced considerably less invasion 
and migration compared with negative control siRNA-transfect-
ed SKOV-3 cells (invasion: 178 ± 17.2 vs 36.2 ± 3.3, P = 0.009; 
migration: 220.4 ± 25.5 vs 57 ± 7.6, P = 0.009).
Conclusion LPA2 has an essential role in LPA-induced uPA acti-
vation and tumor cell invasion in ovarian cancer SKOV-3 cells.
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Lysophosphatidic acid (LPA) is a naturally oc-
curring lysophospholipid, which mediates di-
verse biological responses such as mitogene-
sis, differentiation, cell survival, angiogenesis, 
inflammation, and cell migration (1). Extra-
cellular LPA has been shown to be involved 
in certain diseases, such as atherosclerosis (2) 
and cancer (3-5). In fact, LPA has been iden-
tified as a growth-promoting factor that sup-
ports the proliferation of ovarian cancer cells 
in malignant ascites from ovarian cancer pa-
tients (6,7). Indeed, LPA is present at high 
levels in the ascites of patients with advanced-
stage ovarian cancer, in concentrations of 5-
200 µmol/L (3,8).
Most of the biological responses to LPA are 
mediated through the lipid-specific endothelial 
differentiation gene (EDG) family G protein-
coupled receptors, ie, LPA1/EDG-2, LPA2/
EDG-4, and LPA3/EDG-7 (9-11), although re-
cent studies have suggested that LPA responses 
are potentially mediated through LPA4/GPR23 
(12) and peroxisome proliferator-activated re-
ceptor γ (13). These LPA receptors differ with 
respect to their distribution in various tissues. 
LPA1 is the most widely expressed receptor 
subtype in normal and tumor tissues, whereas 
LPA2 and LPA3 are frequently overexpressed 
in human tumor tissues, such as ovarian cancer, 
gastric cancer, and ductal cancer, which may ac-
count for the various biological effects of LPA 
(9,10,14). Previous studies found that malig-
nant transformation results in aberrant expres-
sion of LPA2 in ovarian and thyroid cancers, 
suggesting that LPA may play a role in tumor 
biology and that shifts in LPA receptor expres-
sion are related to carcinogenesis (4,7).
Proteolysis of extracellular matrix (ECM) 
proteins is necessary for the invasion and me-
tastasis of cancer cells. Urokinase plasmino-
gen activator (uPA), a serine protease, can 
promote degradation of ECM and has been 
shown to correlate inversely with prognosis in 
ovarian cancer patients. In vitro studies have 
shown that uPA expression is induced by LPA 
in ovarian cancer cell lines but not in normal 
ovarian epithelial cell (15,16).
Previous studies showed that overexpres-
sion of LPA2 induced the expressions of active 
uPA and vascular endothelial growth factor in 
the ovaries of transgenic mice (17). In breast 
carcinoma cells, LPA2 was also shown by RNA 
interference approach to mediate LPA-stim-
ulated cell migration (18). However, the ef-
fect of LPA2 on these processes in ovarian can-
cer, especially when LPA2 is inhibited, has not 
been investigated. In the present study, we in-
hibited the endogenous expression of LPA2 
mRNA using specific small interfering RNA 
(siRNA), to investigate more directly the po-
tential role of LPA2 in LPA-induced uPA ac-




1-oleoyl-LPA was purchased from Avanti Po-
lar Lipids Inc (Alabaster, AL, USA). The kit 
for quantification of uPA activity was ob-
tained from American Diagnostica (Green-
wich, CT, USA) and used according to the 
manufacturer’s guidelines.
Cell culture and LPA stimulation
The established ovarian cancer cell line SKOV-
3 was obtained from American Type Culture 
Collection (Manassas, VA, USA). The cells 
were maintained under standard conditions 
(37°C and 5% CO2) in a plastic cell culture 
flasks and grown in RPMI 1640 supplement-
ed with 10% heat-inactivated fetal bovine se-
rum, 1% penicillin, and 1% streptomycin (all 
from Sigma, St. Louis, MO, USA) until their 
confluence level reached about 80%. They 
were then washed twice with prewarmed 
phosphate-buffered saline and cultured in se-
rum-free medium (Invitrogen, Carlsbad, CA, 
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USA) overnight. The appropriate amount of 
LPA was diluted in 1% delipidated bovine se-
rum albumin (Sigma) on ice. After starvation, 
the serum-free medium was replaced, LPA was 
added to the culture at a concentration of 80 
μmol/L, and incubation was carried out at 
37°C for various time periods up to 24 hours. 
In a different experiment, various concentra-
tions of LPA (0-80 μmol/L) were added to the 
culture and incubation was carried out at 37°C 
for 24 hours. Cell culture supernatant was col-
lected and analyzed using uPA enzyme-linked 
immunosorbent assay (ELISA).
uPA ELISA
Extracts were diluted 1:5 in assay buffer and 100 
μL aliquots of each extract were incubated over-
night at 4°C in precoated microtest wells. Wells 
were washed thoroughly with wash buffer and 
a second, biotinylated antibody that recognizes 
a specific epitope on uPA molecule was added 
for each analysis. Wells were washed again after 
an incubation of 1 hour and 100 μL of enzyme 
conjugate was added (streptavidin-conjugated 
horseradish peroxidase), leading to the forma-
tion of the antibody-enzyme detection complex. 
After 1-hour incubation, wells were washed 
again. Then, 100 μL of perborate 3, 3′, 5, 5′-tet-
ramethylbenzidine substrate was added to each 
well and reacted with horseradish peroxidase, 
producing a blue solution. We used 50 μL of 0.5 
mol/L sulfuric acid as a stopping solution, which 
yielded a yellow color in the reaction.
siRNA transfection
The human LPA2 SMARTpool siRNA and 
control non-targeting siRNA were obtained 
from Dharmacon (Lafayette, CO, USA). 
SKOV-3 cells were seeded in 24-well plates 
at a density of 1.25 × 105 cells/well in a com-
plete medium without antibiotics the day be-
fore transfection. The cells were transfect-
ed overnight with control and LPA2-specific 
siRNA (20 pmol) with LipofectAMINETM 
2000 (1µL) (Invitrogen) resuspended in Opti-
MEM (500 µL) (Invitrogen). After transfec-
tion, the cells were incubated with fresh com-
plete medium for 36 hours for recovery, parts 
of the transfected cells were then used for the 
isolation of total cellular RNA followed by 
semiquantitative reverse transcriptase-poly-
merase chain reaction (RT-PCR) analysis of 
LPA2 mRNA level. The remaining cells were 
starved in serum-free medium for 16 hours be-
fore stimulation with LPA. The uPA ELISA, 
Matrigel invasion assay, and cell migration as-
say were performed.
Semiquantitative RT-PCR analysis
The LPA2 and β-actin mRNA levels were eval-
uated by semiquantitative RT-PCR. Brief-
ly, total cellular RNA was extracted by a sin-
gle-step method using TRIzol (Invitrogen). 
For RT-PCR, 10 μg of total RNA was used 
for a 838-bp fragment of LPA2 complemen-
tary DNA (cDNA) synthesis according to the 
manufacturer’s protocol, using 5′-CAATCT-
GCTGGTCATAGC-3′ (forward) and 5′-
AGAGGATGTATAGTGGACAGAC-3′ 
(backward) primer. The primers for β-actin 
(internal control) were also included as fol-
lows: 5′-CCTTCAACACCCCAGCCAT-3′ 
(forward) and 5′-ATGCCAGGGTACATG-
GTGGT-3′ (backward) that amplified a 550-
bp fragment of β-actin cDNA. The PCR cy-
cling parameters were as follows: 5 minutes at 
94°C, followed by 30 cycles of 30 seconds at 
94°C, 45 seconds at 60°C, and 45 seconds at 
72°C, and a final cycle at 72°C for 7 minutes. 
The PCR products were separated by agarose 
gel (1.5%) electrophoresis and stained with 
ethidium bromide. The fluorescence inten-
sity (optical density) was automatically mea-
sured and integrated by gel data acquisition 
AlphaImager HP software (Alpha Innotech 
Corp., San Leandro, CA, USA). A ratio of 
LPA2 and β-actin represented the relative level 
of LPA2 expression.
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In vitro migration and invasion assay
Cell migration was assayed using a Transwell 
chemotaxis chamber (8-μm pore filters). The 
transfected SKOV-3 cells (5 × 104/well) were 
starved for 16 hours. Next, these cells were 
trypsinized and treated with vehicle or 80 
µmol/L LPA and loaded into the top cham-
ber. Fetal bovine serum was then placed into 
the bottom chamber as a chemoattractant. 
Cells were incubated at 37°C in a humidified 
atmosphere and allowed to migrate through 
the chemotaxis chamber for 24 hours. After 
incubation, the cells remaining at the upper 
surface were completely removed using a cot-
ton carrier. The migrated cells on the bottom 
of chemotaxis chamber were stained with he-
matoxylin and eosin. The experiments were 
repeated in triplicate wells and the migrated 
cells were counted microscopically (200 × ) in 
five different fields per filter. Cell invasion ca-
pability was assessed by using a Matrigel inva-
sion chamber (Becton-Dickenson, Bedford, 
MA, USA) according to the manufacturer’s 
instructions. The procedures were essentially 
the same as those for the migration assay using 
Transwell chemotaxis chambers.
Statistical analysis
Results are reported as mean ± standard devia-
tion. Statistical analyses were performed using 
rank-sum test. P<0.05 was considered statis-
tically significant. The Statistical Package for 
the Social Sciences for Windows, version 13.0 
(SPSS, Inc., Chicago, IL, USA) was used to 
perform the analysis.
Results
LPA induces uPA activation in ovarian cancer 
SKOV-3 cells
The treatment of SKOV-3 cells with 80 μmol/
L LPA for 0-24 hours showed that LPA signif-
icantly increased the levels of uPA activity in a 
time-dependent manner (Figure 1A). Also, the 
treatment with increasing concentrations (0-
80 µmol/L) of LPA for 24 hours showed that 
LPA significantly increased the levels of uPA 
activity in a dose-dependent manner (Figure 
1B). These results were consistent with those 
described previously (15,16). A maximum in-
crease in uPA activity when incubated with 
LPA occurred at 24 hours and 80 µmol/L.
Silencing of LPA2 reduces LPA-induced uPA 
activation
SKOV-3 cells were transfected by LPA2-spe-
cific siRNA and control siRNA. The relative 
LPA2 mRNA level was determined by semi-
quantitative RT-PCR analysis. It was shown 
Figure 1. Stimulation of urokinase plasminogen activator (uPA) activ-
ity in SKOV-3 ovarian cancer cells by lysophosphatidic acid (LPA). 
The uPA activity was measured by enzyme-linked immunosorbent 
assay. (A) SKOV-3 cells were incubated with 80 μmol/L lysophos-
phatidic acid (LPA) for 0, 3, 8, 12, and 24 hours before the collec-
tion of conditioned media. (B) SKOV-3 cells in 24-well plates (5 × 105 
per well) were cultured, starved in serum-free medium overnight, and 
incubated with increasing concentrations of LPA (0, 2, 20, 40, and 
80 μmol/L) for 24 hours before the collection of conditioned media. 
Measurements were made in three separate experiments, and data 
are shown as mean ± standard deviation. Asterisk indicates P = 0.004 
vs control. OD – optical density.
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that the transfection with LPA2-specific siR-
NA led to >80% decrease in LPA2 mRNA lev-
els, when compared with non-target control 
siRNA (NC-siRNA) (Figure 2A). Meanwhile, 
we found that the silencing of LPA2 expression 
resulted in ~ 55% reduction in LPA-induced 
uPA activity. In the culture medium without 
LPA stimulation, however, this change was 
minor (Figure 2B).
Down-regulation of LPA2 decreases LPA-induced 
cell invasion
In the culture medium without LPA stimula-
tion, inhibiting LPA2 expression showed no 
significant differences in the invasion activ-
ity of the cells in the NC-siRNA- and LPA2-
specific siRNA-transfected SKOV-3 cells 
(25.0 ± 3.2 vs 25.0 ± 3.7). In the presence of 80 
µmol/L LPA, however, the increase of invasion 
was down-regulated from 7.3-fold in NC-siR-
NA-transfected SKOV-3 cells (178.0 ± 17.2 vs 
25.0 ± 3.2) to 1.7-fold in LPA2 siRNA-trans-
fected SKOV-3 cells (36.2 ± 3.3 vs 25.0 ± 3.7), 
approximately a 4.3-fold decrease in compari-
son with a negative control (178.0 ± 17.2 vs 
36.2 ± 3.3, P = 0.009) (Figure 3A).
Figure 2. Effect of lysophosphatidic acid receptor-2-specific small 
interfering RNA (LPA2-siRNA) transfection on lysophosphatidic acid 
(LPA)-induced urokinase plasminogen activator activity. (A) Semi-
quantitative reverse transcriptase-polymerase chain reaction results 
showed the average knocking down of LPA2 mRNA by siRNA. The 
fragment of LPA2 and β-actin (internal control) cDNA were 838bp 
and 550bp, respectively. (B) Enzyme-linked immunosorbent assay 
showed the decrease of urokinase plasminogen activator (uPA) se-
creted in the presence of 80 μmol/L LPA in LPA2 siRNA-transfected 
SKOV-3 cells compared with non-target control siRNA (NC-siRNA)-
transfected SKOV-3 cells. Measurements were made in three sepa-
rate siRNA transfection experiments, and data were depicted as the 
mean ± standard deviation. Gray bars – NC-siRNA; open bars – LPA2-
siRNA; OD – optical density; asterisk indicates P = 0.004, LPA2-siRNA 
vs NC-siRNA transfection.
Figure 3. Lysophosphatidic acid receptor-2-specific small interfer-
ing RNA (LPA2-siRNA) transfection reduces LPA-induced increase 
of SKOV-3 invasion and migration. (A) Martrigel invasion assay of 
nontarget control and LPA2-siRNA treated with vehicle (0) or LPA 
(80μmol/L). The transfected SKOV-3 ovarian cancer cells were 
starved for 16 hours and then trypsinized and treated with vehicle 
or 80 µmol/L LPA and loaded into the top chamber. The cells were 
incubated at 37°C for 24 hours. The number of cells invaded through 
the Matrigel was counted as described in Material and Methods sec-
tion. (B) The migration activity of the transfected cells was examined 
using Transwell chemotaxis assay. The procedures were essentially 
the same as those for the invasion assay, except that there was no 
Matrigel. Data were depicted as the mean ± standard deviation. As-
terisk indicates P = 0.009, LPA2-siRNA vs non-target control siRNA 
(NC-siRNA) transfection. Gray bars – NC-siRNA; open bars – LPA2-
siRNA.
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Knockdown of LPA2 decreases LPA-induced cell 
migration
The number of migrated cells in the NC-siR-
NA- and LPA2-specific siRNA-transfect-
ed SKOV-3 cells showed no significant dif-
ferences in the absence of LPA (30.0 ± 3.5 vs 
30.0 ± 4.3). However, after being stimulat-
ed with 80 µmol/L LPA, the number of mi-
grated cells was significantly decreased in 
LPA2-specific siRNA-transfected SKOV-3 
cells (57.0 ± 7.6) compared with the NC-siR-
NA-transfected SKOV-3 cells (220.4 ± 25.5; 
P = 0.009) (Figure 3B).
Discussion
In this report, we investigated the effect of 
LPA2 on LPA-induced uPA activation in hu-
man ovarian cancer cell line SKOV-3. The data 
revealed that LPA induced uPA up-regulation 
in a dose- and time-dependent manner. Fur-
ther, we inhibited the expression of LPA2 by 
siRNA technique and found that LPA treat-
ment at 80 μmol/L induced a ~ 55% reduction 
of uPA activity in LPA2-specific siRNA-trans-
fected SKOV-3 cells, when compared with 
control siRNA-transfected SKOV-3 cells. This 
represents an important signaling pathway 
from the LPA2 receptor in the mediation of 
uPA activation by LPA. LPA mediates diverse 
responses by binding to its specific receptors. 
In ovarian cancer, up to 90% tumor specimens 
have been found by Western blot analysis to 
overexpress LPA2 receptor (19).
Degradation of the basement membrane 
is a requisite to the metastasis of tumor cells. 
uPA, a key protease that degrades the base-
ment membrane, has been shown to contrib-
ute to tumor cell invasion. Since the inhibition 
of LPA2 expression could decrease the level of 
uPA, we analyzed the effect of LPA2 on LPA-
induced ovarian cancer invasion. Matrigel in-
vasion assay showed that down-regulation 
of LPA2 expression by siRNA approach in 
SKOV-3 cells was accompanied by 78% inhi-
bition of invasive capacity in response to LPA. 
The result demonstrated that LPA2 played a 
crucial role in LPA-induced ovarian cancer 
cell invasion. Another study also showed that 
LPA2 receptor is overexpressed only in ovari-
an cancer cells and not in normal ovarian ep-
ithelial cells (20). The finding suggested that, 
by inhibiting the LPA2 receptor expression, 
we could interfere in the ovarian cancer cells 
without an impact on normal ovarian surface 
epithelial cells.
The ability of tumor cells to migrate is a 
prerequisite for tumor metastasis. We ob-
served that down-regulation of LPA2 expres-
sion in SKOV-3 cells resulted in 74% decrease 
in the migration capacity of the cells in re-
sponse to LPA, suggesting that the key recep-
tor for this phenomenon was LPA2. A previ-
ous study found that the migration activity of 
pancreatic cancer cells was increased by LPA, 
mainly through LPA1 receptor (5). Shida et al 
(21) also proved that LPA enhanced the mi-
gration of human colon carcinoma DLD1 cells 
by LPA1 receptor, and that LPA1, rather than 
LPA2, was highly expressed in these cell lines. 
In ovarian cancer, however, LPA1 had a minor 
role in LPA-induced cell migration, because it 
was expressed at similar levels in normal ovar-
ian surface epithelial cells and ovarian cancer 
cell lines (14) and the effect was markedly in-
hibited by the down-regulation of LPA2. Our 
results strongly suggested that LPA2 is also ca-
pable of inducing cell migration in ovarian 
cancer cell line SKOV-3, although the mecha-
nism remains unknown.
In summary, our study proved that LPA2 
receptor involved in LPA-dependent uPA ac-
tivation and LPA2 down-regulation signifi-
cantly decreased LPA-induced invasion and 
migration in SKOV-3 ovarian cancer cells. 
These results suggest the importance of LPA2 
in response to LPA-induced pathological ac-
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tions in ovarian cancer cells. Although there 
is not LPA2-selective antagonists at present, 
LPA2 may be a viable target for biological ther-
apy in ovarian cancer. Thus, further research is 
needed to develop a novel LPA2 receptor an-
tagonist and to investigate the role of LPA-
LPA2 axis in tumor growth and metastasis of 
ovarian cancer using mouse xenograft models.
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